Home › Funds › Artia Global Partners LP › TRVI
Artia Global Partners LP position in TRVI
TREVI THERAPEUTICS INC COM · Health Care
Artia Global Partners LP reported holding 2,210,852 shares of TRVI (TREVI THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$41.2M, representing 7.61% of its reported portfolio and ranking #3 among its reported holdings. Artia Global Partners LP has disclosed TRVI holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Artia Global Partners LP's TRVI position evolved
Artia Global Partners LP first disclosed a stake in TRVI in Q2 2025 at 1,311,840 shares (US$7.2M). The position peaked in Q2 2026 at 2,210,852 shares, worth US$41.2M. Across 5 filings, Artia Global Partners LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 2,210,852 shares valued at US$41.2M — an increase of 197,250 shares quarter over quarter.. Notable position changes include a 52% increase in Q3 2025 (shares rose 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.31M | $7.18M | New |
| Q3 2025 | 2.00M | $18.30M | Add |
| Q4 2025 | 2.01M | $25.21M | Add |
| Q1 2026 | 2.01M | $24.02M | Hold |
| Q2 2026 | 2.21M | $41.23M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRVI and 13F data
TRVI (TREVI THERAPEUTICS INC COM) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRVI
- NEA Management Company, LLC 13.22M sh · $246.59M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.94M sh · $185.37M · Q2 2026
- Vivo Capital, LLC 5.09M sh · $95.02M · Q2 2026
- Vestal Point Capital, LP 3.10M sh · $57.81M · Q2 2026
- MPM BioImpact LLC 3.07M sh · $57.32M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 2.66M sh · $49.61M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M sh · $40.00M · Q2 2026
- First Light Asset Management, LLC 2.10M sh · $39.11M · Q2 2026
- Logos Global Management LP 1.88M sh · $35.06M · Q2 2026
- Affinity Asset Advisors, LLC 1.80M sh · $33.57M · Q2 2026
- Siren, L.L.C. 1.79M sh · $33.33M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M sh · $32.50M · Q2 2026
More on Artia Global Partners LP
FAQ
How long has Artia Global Partners LP held TRVI?
Artia Global Partners LP has disclosed TRVI holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is Artia Global Partners LP's current position in TRVI?
As of Q2 2026, Artia Global Partners LP holds 2.21M shares of TRVI (TREVI THERAPEUTICS INC COM), valued at $41.23M, representing 7.61% of its reported portfolio and ranking #3.
Has Artia Global Partners LP been buying or selling TRVI?
In the latest 13F filing (Q2 2026), Artia Global Partners LP increased its position in TRVI. The position peaked in Q2 2026 at 2.21M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.